Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

The in-vitro colorectal cancer screening tests market is set for significant growth, driven by advancements in diagnostics ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

50 million Americans due for colon cancer screening avoid it because they consider traditional tests so unpleasant. But now it can be as simple as a blood test. If you’re overdue for your ...

People are three times more likely to undergo at-home colon cancer screening if they're provided a free test, a new study says. About 30% of patients mailed a free stool test kit completed their ...

Nova Scotia's colorectal cancer screening program sends kits to all Nova Scotians aged ... About 40 per cent of people who receive the tests use them and return them with a fecal sample.

A non-invasive, easy-to-use test, like the Cologuard test, is a simple and effective way to screen for colorectal cancer. In ...

People mailed a free stool test kit are three times more likely to undergo colon cancer screening About 30% of patients sent a free kit completed their screening within six months By comparison, only ...

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has ...